Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Nucleic Acid Testing, Detection of Latent Infection), By End-use (Diagnostic Laboratories, Hospitals), By Region, And Segment Forecasts, 2024 - 2030
Tuberculosis Diagnostics Market Growth & Trends
The global tuberculosis diagnostics market size is expected to reach USD 3.29 billion by 2030, registering a CAGR of 5.97% from 2024 to 2030, according to a new report by Grand View Research, Inc. Advent of advanced diagnostic methods such as Interferon-gamma Release Assay (IGRA), serological methods, and nucleic acid testing have resulted in the high usage rate of diagnostics. Moreover, Point of Care (POC) technologies such as antigen assays are also promoting the diagnosis rate of TB.
These advanced methods including POC diagnostics are affordable, accurate, simple, and yield quick results. Furthermore, the rising burden of TB is the primary factor responsible for the lucrative market growth. As per the World Health Organization, the global estimates of patients afflicted with TB were around 9.6 million in 2014. This high prevalence rate has led the government, healthcare organizations, research institutes, and market players to initiate endeavors directed toward containing the incidence of this infectious disease.
The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This has led to a subsequent upsurge in the demand for diagnostic tests and the TB diagnostics market.
Tuberculosis Diagnostics Market Report Highlights
- Diagnostic laboratories dominated the test type segment with of 46.92% in 2023 as they are cost efficient and easy-to-perform. Diagnostic laboratory tests include smear microscopy and culture-based tests. The high burden regions rely on these methodologies due to their financial and technical incapability to incorporate advanced technologies thus contributing to the growth of the diagnostic laboratory tests segment.
- However, compromised accuracy and the longer processing time are the limiting factor for the diagnostics. Hence, healthcare agencies are striving to implement advanced techniques in the developing regions.
- As a result, nucleic acid tests segment and the latent infection detection segment, which includes skin tests and IGRA, are likely to exhibit a profitable growth rate. These methods overcome the aforementioned limitations thus improving affordability, processing time and accuracy of the diagnostic method.
- Drug resistance in tuberculosis is one of the primary concerns for healthcare professionals as improper treatment due to wrong drug regimen and incorrect dosage forms lead to the development of drug resistance in TB patients undergoing treatment. Hence, the drug resistance detection segment is also anticipated to witness lucrative growth.
- Asia Pacific owing to its huge population base and high burden of TB dominated the global TB diagnostics market in 2015. As per the WHO, countries such as India, China, Afghanistan, and Indonesia are priority regions for control of this communicable disease.
- New product launches, collaboration, mergers & acquisitions, and regional expansion are the key strategic initiatives undertaken by these industry players
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Test Type
- 1.2.2. End-use
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Test type and end-use outlook
- 2.2.2. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Tuberculosis Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing prevalence of TB
- 3.2.1.2. Increasing funding program for TB diagnosis
- 3.2.1.3. Favorable government initiatives for combating TB
- 3.2.1.4. Surge in geriatric population
- 3.2.2. Market restraint analysis
- 3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
- 3.3. Tuberculosis Diagnostics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Tuberculosis Diagnostics Market: Test Type Estimates & Trend Analysis
- 4.1. Global Tuberculosis Diagnostics Market: Test Type Dashboard
- 4.2. Global Tuberculosis Diagnostics Market: Test Type Movement Analysis
- 4.3. Global Tuberculosis Diagnostics Market by Test Type, Revenue
- 4.4. Nucleic Acid Testing
- 4.4.1. Nucleic acid testing market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
- 4.5. Detection of Latent Infection (Skin Test & IGRA)
- 4.5.1. Detection of latent infection (skin test & IGRA) market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
- 4.6. Detection of Drug Resistance (DST)
- 4.6.1. Detection of Drug Resistance (DST) market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
- 4.7. Phage Assay
- 4.7.1. Phase assay market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
- 4.8. Cytokine Detection Assay
- 4.8.1. Cytokine detection assay market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
- 4.9. Diagnostic Laboratory Methods
- 4.9.1. Diagnostic laboratory methods market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
- 4.10. Radiographic Method
- 4.10.1. Radiographic method market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
- 4.11. Other Methods
- 4.11.1. Other methods market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests)
- Chapter 5. Tuberculosis Diagnostics Market: End Use Estimates & Trend Analysis
- 5.1. Global Tuberculosis Diagnostics Market: End Use Dashboard
- 5.2. Global Tuberculosis Diagnostics Market: End Use Movement Analysis
- 5.3. Global Tuberculosis Diagnostics Market by End-use, Revenue
- 5.4. Diagnostic Laboratories
- 5.4.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
- 5.5. Hospitals and Clinics
- 5.5.1. Hospitals and clinics market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
- 5.6. Others
- 5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests)
- Chapter 6. Tuberculosis Diagnostics Market: Regional Estimates & Trend Analysis by Test Type, and End-use
- 6.1. Regional Dashboard
- 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 6.3. North America
- 6.3.1. U.S.
- 6.3.1.1. Key country dynamics
- 6.3.1.2. Regulatory framework/ reimbursement structure
- 6.3.1.3. Competitive scenario
- 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.3.2. Canada
- 6.3.2.1. Key country dynamics
- 6.3.2.2. Regulatory framework/ reimbursement structure
- 6.3.2.3. Competitive scenario
- 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.3.3. Mexico
- 6.3.3.1. Key country dynamics
- 6.3.3.2. Regulatory framework/ reimbursement structure
- 6.3.3.3. Competitive scenario
- 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Key country dynamics
- 6.4.1.2. Regulatory framework/ reimbursement structure
- 6.4.1.3. Competitive scenario
- 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.4.2. Germany
- 6.4.2.1. Key country dynamics
- 6.4.2.2. Regulatory framework/ reimbursement structure
- 6.4.2.3. Competitive scenario
- 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.4.3. France
- 6.4.3.1. Key country dynamics
- 6.4.3.2. Regulatory framework/ reimbursement structure
- 6.4.3.3. Competitive scenario
- 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.4.4. Italy
- 6.4.4.1. Key country dynamics
- 6.4.4.2. Regulatory framework/ reimbursement structure
- 6.4.4.3. Competitive scenario
- 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.4.5. Spain
- 6.4.5.1. Key country dynamics
- 6.4.5.2. Regulatory framework/ reimbursement structure
- 6.4.5.3. Competitive scenario
- 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.4.6. Norway
- 6.4.6.1. Key country dynamics
- 6.4.6.2. Regulatory framework/ reimbursement structure
- 6.4.6.3. Competitive scenario
- 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.4.7. Sweden
- 6.4.7.1. Key country dynamics
- 6.4.7.2. Regulatory framework/ reimbursement structure
- 6.4.7.3. Competitive scenario
- 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.4.8. Denmark
- 6.4.8.1. Key country dynamics
- 6.4.8.2. Regulatory framework/ reimbursement structure
- 6.4.8.3. Competitive scenario
- 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework/ reimbursement structure
- 6.5.1.3. Competitive scenario
- 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.5.2. China
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework/ reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.5.3. India
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework/ reimbursement structure
- 6.5.3.3. Competitive scenario
- 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.5.4. Australia
- 6.5.4.1. Key country dynamics
- 6.5.4.2. Regulatory framework/ reimbursement structure
- 6.5.4.3. Competitive scenario
- 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.5.5. South Korea
- 6.5.5.1. Key country dynamics
- 6.5.5.2. Regulatory framework/ reimbursement structure
- 6.5.5.3. Competitive scenario
- 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.5.6. Thailand
- 6.5.6.1. Key country dynamics
- 6.5.6.2. Regulatory framework/ reimbursement structure
- 6.5.6.3. Competitive scenario
- 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework/ reimbursement structure
- 6.6.1.3. Competitive scenario
- 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.6.2. Argentina
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework/ reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.7. MEA
- 6.7.1. South Africa
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework/ reimbursement structure
- 6.7.1.3. Competitive scenario
- 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.7.2. Saudi Arabia
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework/ reimbursement structure
- 6.7.2.3. Competitive scenario
- 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.7.3. UAE
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework/ reimbursement structure
- 6.7.3.3. Competitive scenario
- 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- 6.7.4. Kuwait
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework/ reimbursement structure
- 6.7.4.3. Competitive scenario
- 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. List of key distributors and channel partners
- 7.3.2. Key customers
- 7.3.3. Key company market share analysis, 2023
- 7.3.4. Abbott
- 7.3.4.1. Company overview
- 7.3.4.2. Financial performance
- 7.3.4.3. Product benchmarking
- 7.3.4.4. Strategic initiatives
- 7.3.5. QIAGEN
- 7.3.5.1. Company overview
- 7.3.5.2. Financial performance
- 7.3.5.3. Product benchmarking
- 7.3.5.4. Strategic initiatives
- 7.3.6. Thermo Fisher Scientific Inc.
- 7.3.6.1. Company overview
- 7.3.6.2. Financial performance
- 7.3.6.3. Product benchmarking
- 7.3.6.4. Strategic initiatives
- 7.3.7. BD
- 7.3.7.1. Company overview
- 7.3.7.2. Financial performance
- 7.3.7.3. Product benchmarking
- 7.3.7.4. Strategic initiatives
- 7.3.8. F. Hoffmann-La Roche AG
- 7.3.8.1. Company overview
- 7.3.8.2. Financial performance
- 7.3.8.3. Product benchmarking
- 7.3.8.4. Strategic initiatives
- 7.3.9. Hologic, Inc.
- 7.3.9.1. Company overview
- 7.3.9.2. Financial performance
- 7.3.9.3. Product benchmarking
- 7.3.9.4. Strategic initiatives
- 7.3.10. Cepheid
- 7.3.10.1. Company overview
- 7.3.10.2. Financial performance
- 7.3.10.3. Product benchmarking
- 7.3.10.4. Strategic initiatives
- 7.3.11. DiaSorin S.p.A.
- 7.3.11.1. Company overview
- 7.3.11.2. Financial performance
- 7.3.11.3. Product benchmarking
- 7.3.11.4. Strategic initiatives
- 7.3.12. Hain Lifescience GmbH
- 7.3.12.1. Company overview
- 7.3.12.2. Financial performance
- 7.3.12.3. Product benchmarking
- 7.3.12.4. Strategic initiatives
- 7.3.13. Oxford Immunotec
- 7.3.13.1. Company overview
- 7.3.13.2. Financial performance
- 7.3.13.3. Product benchmarking
- 7.3.13.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook